Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Brain activity may be biomarker for Rett treatment response

Changes in auditory event-related potentials, or AEPs, the brain’s electrical activity in response to sound, may serve as a non-invasive biomarker to assess treatment response in people with Rett syndrome, a study suggested. Depressed AEPs, as measured by electroencephalography (EEG), which detects the brain’s electrical activity, were normalized when…

NLX-101 aids breathing issues, cognitive deficits in Rett mice

NLX-101 improves breathing and cognitive function in a female mouse model of Rett syndrome, a study found. The potential therapy activates the receptors that bind serotonin, a signaling molecule found at low levels in the brains of Rett patients. “This work provides compelling evidence of the therapeutic potential of…

Computer modeling confirms Daybue dosing regimen

Computer modeling confirms the weight-based dosing strategy for Daybue (trofinetide) to treat people with Rett syndrome, ages 2 and older. That’s according to two, back-to-back studies published separately in Advances in Therapy. Daybue, from Acadia Pharmaceuticals, is the first therapy approved in the U.S. for people with…